ORM-12741, developed by Orion Corporation in collaboration with Janssen Pharmaceuticals, targets agitation and aggression symptoms in Alzheimer's disease, a significant unmet need in the market. The Alzheimer's disease therapeutics market is projected to grow substantially, driven by increasing prevalence and demand for effective treatments. The competitive landscape includes established therapies like cholinesterase inhibitors and memantine, but there remains a gap for targeted neuropsychiatric symptom management. Successful outcomes from this trial could position ORM-12741 as a novel treatment option, potentially enhancing Orion's portfolio and market share in the neurodegenerative disease space.